Correlation between elevated serum interleukin-1β, interleukin-16 levels and psychiatric symptoms in patients with schizophrenia at different stages
Abstract Background There is increasing evidence that immune dysfunction plays an important role in the pathogenesis of schizophrenia. Meso Scale Discovery (MSD) is bioanalytical method, which can detect serum inflammatory factors in patients. MSD has higher sensitivities, capturing a narrower range...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-023-04896-5 |
| _version_ | 1797811321538871296 |
|---|---|
| author | Xialong Cheng Yu Xie Anzhen Wang Cuizhen Zhu Fanfan Yan Wenzhi Pei Xulai Zhang |
| author_facet | Xialong Cheng Yu Xie Anzhen Wang Cuizhen Zhu Fanfan Yan Wenzhi Pei Xulai Zhang |
| author_sort | Xialong Cheng |
| collection | DOAJ |
| description | Abstract Background There is increasing evidence that immune dysfunction plays an important role in the pathogenesis of schizophrenia. Meso Scale Discovery (MSD) is bioanalytical method, which can detect serum inflammatory factors in patients. MSD has higher sensitivities, capturing a narrower range of proteins compared to other methods typically used in similar studies. The present study was aimed to explore the correlation between the levels of serum inflammatory factors and psychiatric symptoms in patients with schizophrenia at different stages and investigate a wide panel of inflammatory factors as independent factors for the pathogenesis of schizophrenia. Methods We recruited 116 participants, including patients with first-episode schizophrenia (FEG, n = 40), recurrence patients (REG, n = 40) with relapse-episode schizophrenia, and a control group (healthy people, HP, n = 36). Patients are diagnosed according to the DSM -V. The plasma levels of IFN-γ, IL-10, IL-1β, IL-2, IL-6, TNF-α, CRP, VEGF, IL-15, and IL-16 were tested by the MSD technique. Patient-related data was collected, including sociodemographic data, positive and negative symptom scale (PANSS), and brief psychiatric rating scale (BPRS) and subscale scores. The independent sample T test, χ2 test, Analysis of covariance (ANCOVA), the least significant difference method (LSD), Spearman’s correlation test, binary logistic regression analysis and ROC curve analysis were used in this study. Results There were significant differences in serum IL-1β (F = 2.37, P = 0.014) and IL-16 (F = 4.40, P < 0.001) levels among the three groups. The level of serum IL-1β in the first-episode group was significantly higher than in the recurrence group (F = 0.87, P = 0.021) and control group (F = 2.03, P = 0.013), but there was no significant difference between the recurrence group and control group (F = 1.65, P = 0.806). The serum IL-16 levels in the first-episode group (F = 1.18, P < 0.001) and the recurrence group (F = 0.83, P < 0.001) were significantly higher than in the control group, and there was no significant difference between the first-episode group and the recurrence group (F = 1.65, P = 0.61). Serum IL-1β was negatively correlated with the general psychopathological score (GPS) of PANSS (R=-0.353, P = 0.026). In the recurrence group, serum IL-16 was positively correlated with the negative score (NEG) of the PANSS scale (R = 0.335, P = 0.035) and negatively correlated with the composite score (COM) (R=-0.329, P = 0.038). In the study, IL-16 levels were an independent variable of the onset of schizophrenia both in the first-episode (OR = 1.034, P = 0.002) and recurrence groups (OR = 1.049, P = 0.003). ROC curve analysis showed that the areas under IL-16(FEG) and IL-16(REG) curves were 0.883 (95%CI:0.794–0.942) and 0.887 (95%CI:0.801–0.950). Conclusions Serum IL-1β and IL-16 levels were different between patients with schizophrenia and healthy people. Serum IL-1β levels in first-episode schizophrenia and serum IL-16 levels in relapsing schizophrenia were correlated with the parts of psychiatric symptoms. The IL-16 level may be an independent factor associating with the onset of schizophrenia. |
| first_indexed | 2024-03-13T07:21:57Z |
| format | Article |
| id | doaj.art-271f49b578d54fa3bfab91cf2c62ad7d |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-03-13T07:21:57Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-271f49b578d54fa3bfab91cf2c62ad7d2023-06-04T11:35:48ZengBMCBMC Psychiatry1471-244X2023-06-0123111010.1186/s12888-023-04896-5Correlation between elevated serum interleukin-1β, interleukin-16 levels and psychiatric symptoms in patients with schizophrenia at different stagesXialong Cheng0Yu Xie1Anzhen Wang2Cuizhen Zhu3Fanfan Yan4Wenzhi Pei5Xulai Zhang6Affiliated Psychological Hospital of Anhui Medical UniversityDepartment of Psychology, School of Educational Science, Anhui Normal UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAbstract Background There is increasing evidence that immune dysfunction plays an important role in the pathogenesis of schizophrenia. Meso Scale Discovery (MSD) is bioanalytical method, which can detect serum inflammatory factors in patients. MSD has higher sensitivities, capturing a narrower range of proteins compared to other methods typically used in similar studies. The present study was aimed to explore the correlation between the levels of serum inflammatory factors and psychiatric symptoms in patients with schizophrenia at different stages and investigate a wide panel of inflammatory factors as independent factors for the pathogenesis of schizophrenia. Methods We recruited 116 participants, including patients with first-episode schizophrenia (FEG, n = 40), recurrence patients (REG, n = 40) with relapse-episode schizophrenia, and a control group (healthy people, HP, n = 36). Patients are diagnosed according to the DSM -V. The plasma levels of IFN-γ, IL-10, IL-1β, IL-2, IL-6, TNF-α, CRP, VEGF, IL-15, and IL-16 were tested by the MSD technique. Patient-related data was collected, including sociodemographic data, positive and negative symptom scale (PANSS), and brief psychiatric rating scale (BPRS) and subscale scores. The independent sample T test, χ2 test, Analysis of covariance (ANCOVA), the least significant difference method (LSD), Spearman’s correlation test, binary logistic regression analysis and ROC curve analysis were used in this study. Results There were significant differences in serum IL-1β (F = 2.37, P = 0.014) and IL-16 (F = 4.40, P < 0.001) levels among the three groups. The level of serum IL-1β in the first-episode group was significantly higher than in the recurrence group (F = 0.87, P = 0.021) and control group (F = 2.03, P = 0.013), but there was no significant difference between the recurrence group and control group (F = 1.65, P = 0.806). The serum IL-16 levels in the first-episode group (F = 1.18, P < 0.001) and the recurrence group (F = 0.83, P < 0.001) were significantly higher than in the control group, and there was no significant difference between the first-episode group and the recurrence group (F = 1.65, P = 0.61). Serum IL-1β was negatively correlated with the general psychopathological score (GPS) of PANSS (R=-0.353, P = 0.026). In the recurrence group, serum IL-16 was positively correlated with the negative score (NEG) of the PANSS scale (R = 0.335, P = 0.035) and negatively correlated with the composite score (COM) (R=-0.329, P = 0.038). In the study, IL-16 levels were an independent variable of the onset of schizophrenia both in the first-episode (OR = 1.034, P = 0.002) and recurrence groups (OR = 1.049, P = 0.003). ROC curve analysis showed that the areas under IL-16(FEG) and IL-16(REG) curves were 0.883 (95%CI:0.794–0.942) and 0.887 (95%CI:0.801–0.950). Conclusions Serum IL-1β and IL-16 levels were different between patients with schizophrenia and healthy people. Serum IL-1β levels in first-episode schizophrenia and serum IL-16 levels in relapsing schizophrenia were correlated with the parts of psychiatric symptoms. The IL-16 level may be an independent factor associating with the onset of schizophrenia.https://doi.org/10.1186/s12888-023-04896-5SchizophreniaInterleukin-1βInterleukin-16Meso Scale DiscoveryPsychiatric symptoms |
| spellingShingle | Xialong Cheng Yu Xie Anzhen Wang Cuizhen Zhu Fanfan Yan Wenzhi Pei Xulai Zhang Correlation between elevated serum interleukin-1β, interleukin-16 levels and psychiatric symptoms in patients with schizophrenia at different stages BMC Psychiatry Schizophrenia Interleukin-1β Interleukin-16 Meso Scale Discovery Psychiatric symptoms |
| title | Correlation between elevated serum interleukin-1β, interleukin-16 levels and psychiatric symptoms in patients with schizophrenia at different stages |
| title_full | Correlation between elevated serum interleukin-1β, interleukin-16 levels and psychiatric symptoms in patients with schizophrenia at different stages |
| title_fullStr | Correlation between elevated serum interleukin-1β, interleukin-16 levels and psychiatric symptoms in patients with schizophrenia at different stages |
| title_full_unstemmed | Correlation between elevated serum interleukin-1β, interleukin-16 levels and psychiatric symptoms in patients with schizophrenia at different stages |
| title_short | Correlation between elevated serum interleukin-1β, interleukin-16 levels and psychiatric symptoms in patients with schizophrenia at different stages |
| title_sort | correlation between elevated serum interleukin 1β interleukin 16 levels and psychiatric symptoms in patients with schizophrenia at different stages |
| topic | Schizophrenia Interleukin-1β Interleukin-16 Meso Scale Discovery Psychiatric symptoms |
| url | https://doi.org/10.1186/s12888-023-04896-5 |
| work_keys_str_mv | AT xialongcheng correlationbetweenelevatedseruminterleukin1binterleukin16levelsandpsychiatricsymptomsinpatientswithschizophreniaatdifferentstages AT yuxie correlationbetweenelevatedseruminterleukin1binterleukin16levelsandpsychiatricsymptomsinpatientswithschizophreniaatdifferentstages AT anzhenwang correlationbetweenelevatedseruminterleukin1binterleukin16levelsandpsychiatricsymptomsinpatientswithschizophreniaatdifferentstages AT cuizhenzhu correlationbetweenelevatedseruminterleukin1binterleukin16levelsandpsychiatricsymptomsinpatientswithschizophreniaatdifferentstages AT fanfanyan correlationbetweenelevatedseruminterleukin1binterleukin16levelsandpsychiatricsymptomsinpatientswithschizophreniaatdifferentstages AT wenzhipei correlationbetweenelevatedseruminterleukin1binterleukin16levelsandpsychiatricsymptomsinpatientswithschizophreniaatdifferentstages AT xulaizhang correlationbetweenelevatedseruminterleukin1binterleukin16levelsandpsychiatricsymptomsinpatientswithschizophreniaatdifferentstages |